Phone: 614/488-2118
Fax: 614/488-2647

1335 Dublin Rd., Suite 124A
Columbus, OH 43215

Protocol Categories

View All Protocols


Melanoma / Skin-Other

Alliance A091605
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
Alliance A091802
Phase II randomized trial of avelumab plus cetuximab versus avelumab alone in advanced cutaneous squamous cell carcinoma of the skin (cSCC)
ECOG EA6134
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) A Phase III Trial
NCCTG N0392
Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials
SWOG S1320
A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NCS-763760) and Trametinib (NCS-763093) in BRAFV600E/K Mutant Melanoma
SWOG S1512
A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)
SWOG S1616
A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
SWOG S1801
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma